Literature DB >> 28686147

Surgical management of spinal osteoblastomas.

Anne L Versteeg1, Nicolas Dea2, Stefano Boriani3, Peter P Varga4, Alessandro Luzzati5, Michael G Fehlings6, Mark H Bilsky7, Laurence D Rhines8, Jeremy J Reynolds9, Mark B Dekutoski10, Ziya L Gokaslan11, Niccole M Germscheid12, Charles G Fisher13.   

Abstract

OBJECTIVE Osteoblastoma is a rare primary benign bone tumor with a predilection for the spinal column. Although of benign origin, osteoblastomas tend to behave more aggressively clinically than other benign tumors. Because of the low incidence of osteoblastomas, evidence-based treatment guidelines and high-quality research are lacking, which has resulted in inconsistent treatment. The goal of this study was to determine whether application of the Enneking classification in the management of spinal osteoblastomas influences local recurrence and survival time. METHODS A multicenter database of patients who underwent surgical intervention for spinal osteoblastoma was developed by the AOSpine Knowledge Forum Tumor. Patient data pertaining to demographics, diagnosis, treatment, cross-sectional survival, and local recurrence were collected. Patients in 2 cohorts, based on the Enneking classification of the tumor (Enneking appropriate [EA] and Enneking inappropriate [EI]), were analyzed. If the final pathology margin matched the Enneking-recommended surgical margin, the tumor was classified as EA; if not, it was classified as EI. RESULTS A total of 102 patients diagnosed with a spinal osteoblastoma were identified between November 1991 and June 2012. Twenty-nine patients were omitted from the analysis because of short follow-up time, incomplete survival data, or invalid staging, which left 73 patients for the final analysis. Thirteen (18%) patients suffered a local recurrence, and 6 (8%) patients died during the study period. Local recurrence was strongly associated with mortality (relative risk 9.2; p = 0.008). When adjusted for Enneking appropriateness, this result was not altered significantly. No significant differences were found between the EA and EI groups in regard to local recurrence and mortality. CONCLUSIONS In this evaluation of the largest multicenter cohort of spinal osteoblastomas, local recurrence was found to be strongly associated with mortality. Application of the Enneking classification as a treatment guide for preventing local recurrence was not validated.

Entities:  

Keywords:  EA = Enneking appropriate; EI = Enneking inappropriate; Enneking classification; WBB = Weinstein-Boriani-Biagini; local recurrence; osteoblastoma; primary spine tumor; prognostic factors; spinal oncology; surgical treatment; survival

Mesh:

Year:  2017        PMID: 28686147     DOI: 10.3171/2017.1.SPINE16788

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  4 in total

1.  Neoadjuvant denosumab for the treatment of a sacral osteoblastoma.

Authors:  Jeremy J Reynolds; Dominique A Rothenfluh; Nick Athanasou; Shaun Wilson; David C Kieser
Journal:  Eur Spine J       Date:  2018-01-22       Impact factor: 3.134

2.  Intralesional Marginal Resection for Osteoblastoma in the Mobile Spine: Experience From a Single Center.

Authors:  Shiliang Cao; Keyuan Chen; Liang Jiang; Feng Wei; Xiaoguang Liu; Zhongjun Liu
Journal:  Front Surg       Date:  2022-06-06

3.  Recurrent lumbar-origin osteoblastoma treated with multiple surgery and carbon ion radiotherapy: a case report.

Authors:  Akira Honda; Yoichi Iizuka; Reiko Imai; Masahiro Nishinome; Junko Hirato; Hiromi Koshi; Tokue Mieda; Hiroyuki Sonoda; Sho Ishiwata; Yohei Kakuta; Tsuyoshi Tajika; Hirotaka Chikuda
Journal:  BMC Musculoskelet Disord       Date:  2020-05-22       Impact factor: 2.362

4.  Imaging algorithm and multimodality evaluation of spinal osteoblastoma.

Authors:  Zihuan Huang; Tingsong Fang; Zhiguang Si; Youcai Li; Lan Zhang; Chunling Zheng; Shenmei Li; Manting Su; Xiaomin Liu; Xiaodan Li; Yuankui Wu
Journal:  BMC Musculoskelet Disord       Date:  2020-04-14       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.